Teknova Q3 Revenue Up 22% to $12.7M, Raises 2026 Revenue Guidance to $46-48M
TKNO has more than doubled off its 52-week low of $1.91.
Summary
Teknova reported Q3 2026 revenue of $12.7M, up 22%, and raised 2026 revenue guidance to $46-48M while reaffirming free cash outflow under $8M. The quarter closed with $16.6M of cash and short-term investments after a $46.0M gross October equity raise.
Key Events · Earnings and Guidance · TKNO
-
Q3 Revenue Beats at $12.7M
Total revenue rose 22% to $12.704M from $10.454M a year earlier, with Clinical Solutions up 86% to $3.168M and Lab Essentials up 9% to $9.034M.
-
2026 Revenue Guidance Raised
Full-year 2026 revenue guidance is now $46-48M, up from the $12.5-12.7M Q3 range pre-announced on 2026-10-20; free cash outflow guidance held at less than $8M.
-
Margins and Loss Improve
Gross margin expanded to 38.0% from 30.7%, net loss narrowed to $3.490M (-$0.06 per share) from $4.286M (-$0.08), and Adjusted EBITDA improved to -$0.996M from -$1.576M.
-
October Raise Closed at $46M Gross
The offering closed 2026-10-22 at 9,200,000 shares and $5.00 per share, including the full underwriters' option, for $46.0M gross and about $42.9M net — larger than the 8M-share, $40M deal first reported.
Analysis · TKNO · Life Sciences
Teknova beat its own pre-announcement and lifted full-year revenue guidance to $46-48M, with gross margin jumping to 38.0% from 30.7% and net loss narrowing to $3.5M. The October raise closed larger than first announced — 9.2M shares at $5.00 for $46.0M gross, about $42.9M net — which, against $16.6M of cash and short-term investments and $13.2M of borrowings at quarter end, funds the sub-$8M free cash outflow plan without near-term financing pressure. The open question is whether the biotech funding recovery management cites in small and mid-sized customer orders holds through year-end.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TKNO was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $454.7M. The 52-week trading range was $1.91 to $9.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.